Status:

COMPLETED

Evaluating the Effectiveness of Neupro® (Rotigotine) and L-dopa Combination Therapy in Patients With Parkinson's Disease

Lead Sponsor:

UCB Biopharma S.P.R.L.

Collaborating Sponsors:

PRA Health Sciences

Conditions:

Idiopathic Parkinson's Disease

Eligibility:

All Genders

18+ years

Brief Summary

This study aims to evaluate the effectiveness of Rotigotine and Levodopa combination therapy for younger and older patients with Parkinson's Disease under real life conditions. Effects on ability to p...

Eligibility Criteria

Inclusion

  • The following selection criteria must be followed for patients entering the Noninterventional Study (NIS):
  • The decision by the treating physician to prescribe Rotigotine transdermal patch is made before participating in the NIS due to a clinical therapeutic indication (e.g., because of intolerance and/or ineffectiveness of another dopamine agonist)
  • The patient is either male or female and over 18 years of age
  • A Patient Data Consent form is signed and dated by the patient or by the legal representative
  • The patient has idiopathic Parkinson's Disease, has not received Rotigotine within 28 days prior to the Baseline Visit and is willing to participate in questionnaire based assessments
  • The patient is receiving L-dopa as monotherapy or a combination therapy composed of L-dopa and a dopamine agonist other than Rotigotine
  • The patient has been on L-dopa therapy for at least 6 months and is responding to initial L-dopa therapy
  • The patient has a Hoehn and Yahr stage score of 1 to 4.

Exclusion

  • Patients will be excluded from the study if they have participated in a clinical study of a medication or a medical device within 3 months prior to Baseline or if they are participating in a clinical study at the time of inclusion or have already participated in the current study.

Key Trial Info

Start Date :

September 1 2014

Trial Type :

OBSERVATIONAL

Allocation :

ACTUAL

End Date :

June 1 2016

Estimated Enrollment :

195 Patients enrolled

Trial Details

Trial ID

NCT02227355

Start Date

September 1 2014

End Date

June 1 2016

Last Update

July 4 2016

Active Locations (42)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 11 (42 locations)

1

42

Lille, France

2

41

Mougins, France

3

40

Nîmes, France

4

6

Alzenau in Unterfranken, Germany

Evaluating the Effectiveness of Neupro® (Rotigotine) and L-dopa Combination Therapy in Patients With Parkinson's Disease | DecenTrialz